# A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT06512051** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 248 (estimated)

## Conditions studied

- Advanced or Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** SHR-A2102 for Injection
- **DRUG:** Adebrelimab Injection
- **DRUG:** Cisplatin injection
- **DRUG:** Carboplatin injection
- **DRUG:** Bevacizumab Injection

## Key facts

- **NCT ID:** NCT06512051
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-30
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 248 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06512051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06512051, "A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06512051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*